المؤلفون: Frede Donskov, Cathy Anne Pinto, Raluca Predoiu, Claire Fox, Jeanette Baehr Georgsen, Katrine Skaarup, Mehmet Burcu, Rodolfo Perini, Torben Steiniche

المصدر: Donskov, F, Pinto, C A, Predoiu, R, Fox, C, Georgsen, J B, Skaarup, K, Burcu, M, Perini, R & Steiniche, T 2022, ' Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma ', Acta Oncologica, vol. 61, no. 10, pp. 1268-1277 . https://doi.org/10.1080/0284186X.2022.2119100Test

مصطلحات موضوعية: RNA, Messenger/genetics, Hematology, General Medicine, Prognosis, Kidney Neoplasms/genetics, B7-H1 Antigen, Kidney Neoplasms, Oncology, Carcinoma, Renal Cell/drug therapy, Humans, Radiology, Nuclear Medicine and imaging, RNA, Messenger, Hypoxia, Carcinoma, Renal Cell, B7-H1 Antigen/genetics

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::544e13b279d9c7d4b03f0b17b9050b63Test
https://pubmed.ncbi.nlm.nih.gov/36112410Test

المؤلفون: Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard

المساهمون: Cancer Research and Personalized Medicine - CARPEM [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie [Paris] (ARTIC), Institut Mutualiste de Montsouris (IMM), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital Saint-André, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Eugène Marquis (CRLCC), Institut de Cancérologie de Strasbourg Europe (ICANS), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), Clinique d'Oncologie et de Radiothérapie [Tours] (CORAD), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Foch [Suresnes], Service des Explorations Fonctionnelles Physiologiques [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hospices Civils de Lyon (HCL), Nouvel Hôpital Civil de Strasbourg, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)

المصدر: Lancet Oncology
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩

مصطلحات موضوعية: MESH: Humans, MESH: Carcinoma, Renal Cell / drug therapy, MESH: Angiogenesis Inhibitors / adverse effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Neoplasm Staging, MESH: Male, MESH: Prospective Studies, MESH: Ipilimumab, MESH: Lipase, Oncology, MESH: Tumor Microenvironment, MESH: Sunitinib, MESH: Biomarkers, MESH: Antineoplastic Combined Chemotherapy Protocols / adverse effects, MESH: Female, MESH: Nivolumab / adverse effects, MESH: Protein Kinase Inhibitors / adverse effects

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a85c6d4558df8a8fb1a475ca37c2014Test
https://hal.science/hal-04072026Test

المؤلفون: Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid

المصدر: Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063Test

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, DOXORUBICIN, Population, Ipilimumab, Protein Serine-Threonine Kinases, Sunitinib/therapeutic use, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, PD-1, Antineoplastic Combined Chemotherapy Protocols, Post-hoc analysis, Sunitinib, Carcinoma, medicine, Humans, Hippo Signaling Pathway, education, Carcinoma, Renal Cell, education.field_of_study, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nivolumab/adverse effects, medicine.disease, SYSTEMIC THERAPY, Kidney Neoplasms, Confidence interval, Kidney Neoplasms/drug therapy, Editorial Commentary, Nivolumab, 030104 developmental biology, ANTIBODY, GEMCITABINE, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, SURVIVAL, Ipilimumab/adverse effects, Immunotherapy, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25aTest
https://doi.org/10.1158/1078-0432.ccr-20-2063Test

المؤلفون: Toni K. Choueiri, Howard Gurney, David F. McDermott, Christian Kollmannsberger, Michael A. Carducci, Martin Eduardo Richardet, M. Brent McHenry, Elizabeth R. Plimack, Fabio A.B. Schutz, David Cella, Nizar M. Tannir, Frede Donskov, Bernard Escudier, John Wagstaff, Yoshihiko Tomita, Robert J. Motzer, Satoshi Fukasawa, Shruti Shally Saggi, Saby George, Giuseppe Procopio, Christine Chevreau, Hans J. Hammers, Thomas Gauler, Daniel Castellano, Jeffrey A. Sosman, James Larkin, Ajjai Alva, Sandhya Srinivas, Katriina Peltola, Scott S. Tykodi, Stéphane Oudard

المصدر: Cancer
Motzer, R J, Escudier, B, George, S, Hammers, H J, Srinivas, S, Tykodi, S S, Sosman, J A, Plimack, E R, Procopio, G, McDermott, D F, Castellano, D, Choueiri, T K, Donskov, F, Gurney, H, Oudard, S, Richardet, M, Peltola, K, Alva, A S, Carducci, M, Wagstaff, J, Chevreau, C, Fukasawa, S, Tomita, Y, Gauler, T C, Kollmannsberger, C K, Schutz, F A, Larkin, J, Cella, D, McHenry, M B, Saggi, S S & Tannir, N M 2020, ' Nivolumab versus everolimus in patients with advanced renal cell carcinoma : Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial ', Cancer, vol. 126, no. 18, pp. 4156-4167 . https://doi.org/10.1002/cncr.33033Test

مصطلحات موضوعية: CheckMate 025, Male, Oncology, Cancer Research, Medizin, immune checkpoint inhibitor, DOSE RECOMBINANT INTERLEUKIN-2, 0302 clinical medicine, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Medicine, 030212 general & internal medicine, Everolimus/pharmacology, Hazard ratio, Kidney Neoplasms, 3. Good health, Kidney Neoplasms/drug therapy, Nivolumab, Treatment Outcome, Tolerability, SAFETY, 030220 oncology & carcinogenesis, SURVIVAL, Female, medicine.drug, medicine.medical_specialty, Antineoplastic Combined Chemotherapy Protocols/pharmacology, previously treated, Article, 03 medical and health sciences, Nivolumab/pharmacology, Internal medicine, Humans, Everolimus, Adverse effect, Carcinoma, Renal Cell, nivolumab, business.industry, everolimus, medicine.disease, LIFE, Carcinoma, Renal Cell/drug therapy, business, Kidney cancer, advanced renal cell carcinoma (aRCC), Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450b91a3d1c37a04675ddfa5f89f7897Test
https://doi.org/10.1002/cncr.33033Test

المؤلفون: Chun L. Gan, Daniel E. Meyers, Heidi A. I. Grosjean, Aliyah Pabani, Tina Cheng, Toni K. Choueiri, Sumanta K. Pal, Daniel Y.C. Heng, Naveen S. Basappa, Frede Donskov, Michael Sander, Lori Wood, Igor Stukalin, Shaan Dudani, S. Dolter, Siddhartha Goutam, Connor Wells, Jose Gerard Monzon, Benjamin W. Ewanchuk, Don Morris

المصدر: Gan, C L, Stukalin, I, Meyers, D E, Dudani, S, Grosjean, H A I, Dolter, S, Ewanchuk, B W, Goutam, S, Sander, M, Wells, C, Pabani, A, Cheng, T, Monzon, J, Morris, D, Basappa, N S, Pal, S K, Wood, L A, Donskov, F, Choueiri, T K & Heng, D Y C 2021, ' Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials ', European Journal of Cancer, vol. 151, pp. 115-125 . https://doi.org/10.1016/j.ejca.2021.04.004Test

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Skin Neoplasms, Time Factors, Databases, Factual, Carcinoma, Non-Small-Cell Lung/drug therapy, medicine.medical_treatment, Eligibility Determination, 0302 clinical medicine, RENAL-CELL CARCINOMA, Renal cell carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Clinical outcomes, Skin Neoplasms/drug therapy, IMDC, METASTATIC MELANOMA, Melanoma/drug therapy, Immune Checkpoint Inhibitors, Melanoma, education.field_of_study, Clinical Trials as Topic, CHEMOTHERAPY, Middle Aged, CANCER, Kidney Neoplasms, Kidney Neoplasms/drug therapy, Treatment Outcome, 030220 oncology & carcinogenesis, SURVIVAL, Female, Immunotherapy, medicine.medical_specialty, Real-world patients, RANDOMIZED CONTROLLED-TRIALS, Population, 03 medical and health sciences, Trial eligibility, Immune Checkpoint Inhibitors/adverse effects, Internal medicine, medicine, Humans, education, Lung cancer, PEMBROLIZUMAB, Lung Neoplasms/drug therapy, Carcinoma, Renal Cell, Retrospective Studies, Aged, Solid tumour, Performance status, business.industry, Non–small-cell lung cancer, IPILIMUMAB, Patient Selection, Clinical trial ineligible, Immuno-oncology, medicine.disease, Neoplasms/drug therapy, Clinical trial, 030104 developmental biology, COMBINED NIVOLUMAB, Carcinoma, Renal Cell/drug therapy, business, Non-small-cell lung cancer, REAL-WORLD

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb68feab4d3e27cdcf4e38239ab4d0c5Test
https://pure.au.dk/portal/da/publications/outcomes-of-patients-with-solid-tumour-malignancies-treated-with-firstline-immunooncology-agents-who-do-not-meet-eligibility-criteria-for-clinical-trialsTest(049edcae-1ed9-4e12-b16e-97de3ae12c00).html

المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators

المساهمون: Gennigens, Christine

المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)

مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie

العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406

الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test

المؤلفون: David F. McDermott, Jae-Lyun Lee, Georg A. Bjarnason, James M. G. Larkin, Rustem A. Gafanov, Mark D. Kochenderfer, Niels Viggo Jensen, Frede Donskov, Jahangeer Malik, Alexandr Poprach, Scott S. Tykodi, Teresa Alonso-Gordoa, Daniel C. Cho, Poul F. Geertsen, Miguel Angel Climent Duran, Christopher DiSimone, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins

المصدر: McDermott, D F, Lee, J L, Bjarnason, G A, Larkin, J M G, Gafanov, R A, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, DiSimone, C, Silverman, R K, Perini, R F, Schloss, C & Atkins, M B 2021, ' Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 39, no. 9, pp. 1020-1028 . https://doi.org/10.1200/JCO.20.02363Test
McDermott, D F, Lee, J L, Bjarnason, G A, Larkin, J M G, Gafanov, R A, Kochenderfer, M D, Jensen, N V, Donskov, F, Malik, J, Poprach, A, Tykodi, S S, Alonso-Gordoa, T, Cho, D C, Geertsen, P F, Climent Duran, M A, DiSimone, C, Silverman, R K, Perini, R F, Schloss, C & Atkins, M B 2021, ' Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma ', Journal of Clinical Oncology, vol. 39, no. 9, pp. 1020-1028 . https://doi.org/10.1200/JCO.20.02363Test

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, Non-Randomized Controlled Trials as Topic, education, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Humans, Antineoplastic Agents, Immunological/therapeutic use, Carcinoma, Renal Cell, Aged, Aged, 80 and over, Middle Aged, Prognosis, Kidney Neoplasms, Survival Rate, Kidney Neoplasms/drug therapy, 030104 developmental biology, Antibodies, Monoclonal, Humanized/therapeutic use, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, Female, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df891535cd8598712754ea270af1095cTest
https://findresearcher.sdu.dk:8443/ws/files/181944398/jco.20.02363.pdfTest

المؤلفون: Subrina Farah, Ziad Bakouny, Toni K. Choueiri, Frede Donskov, Daniel Y.C. Heng, Aly-Khan A. Lalani, Shaan Dudani

المصدر: JAMA Oncol
Lalani, A K A, Bakouny, Z, Farah, S, Donskov, F, Dudani, S, Heng, D Y C & Choueiri, T K 2021, ' Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma ', JAMA Oncology, vol. 7, no. 5, pp. 773-775 . https://doi.org/10.1001/jamaoncol.2021.0019Test

مصطلحات موضوعية: Cancer Research, business.industry, Immune checkpoint inhibitors, MEDLINE, Genomics, biochemical phenomena, metabolism, and nutrition, medicine.disease, Genome, Kidney Neoplasms, Body Mass Index, Kidney Neoplasms/drug therapy, Text mining, Oncology, Renal cell carcinoma, Carcinoma, Renal Cell/drug therapy, Cancer research, Research Letter, Medicine, Humans, business, Body mass index, Carcinoma, Renal Cell, Immune Checkpoint Inhibitors, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b0f12d3ce8ea9dbc648354c3a65db23Test
https://europepmc.org/articles/PMC7934079Test/

المؤلفون: Bohuslav Melichar, Hong Zhang, Frede Donskov, Sergei Varlamov, Christian Doehn, Agnieszka Michael, Ray McDermott, Toni K. Choueiri, Simon Chowdhury, M. Neil Reaume, Evgeny Kopyltsov, Paola Aimone, Robert J. Motzer, Marine Gross-Goupil, Arnulf Stenzl, Paul Russo, Cora N. Sternberg, Brian I. Rini, Naomi B. Haas, Ho Yeong Lim, Milada Zemanova, Lori Wood, Miguel Izquierdo, Jae-Lyun Lee

المصدر: Motzer, R J, Russo, P, Haas, N, Doehn, C, Donskov, F, Gross-Goupil, M, Varlamov, S, Kopyltsov, E, Lee, J L, Lim, H Y, Melichar, B, Zemanova, M, Rini, B, Choueiri, T K, Wood, L, Reaume, M N, Stenzl, A, Chowdhury, S, McDermott, R, Michael, A, Izquierdo, M, Aimone, P, Zhang, H & Sternberg, C N 2021, ' Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma : Final Overall Survival Analysis of the Phase 3 PROTECT Trial ', European Urology, vol. 79, no. 3, pp. 334-338 . https://doi.org/10.1016/j.eururo.2020.12.029Test

مصطلحات موضوعية: medicine.medical_specialty, Indazoles, Urology, medicine.medical_treatment, 030232 urology & nephrology, Phases of clinical research, Tyrosine kinase inhibitor, Placebo, Nephrectomy, Disease-Free Survival, Pazopanib, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Interquartile range, medicine, Adjuvant therapy, Neoplasm Recurrence, Local/prevention & control, Humans, Carcinoma, Renal Cell, Sulfonamides, business.industry, Hazard ratio, medicine.disease, Kidney Neoplasms, HIGH-RISK, Kidney Neoplasms/drug therapy, Pyrimidines, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, Neoplasm Recurrence, Local, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e65985be16fd652ec1915b66d0f0749cTest
https://pure.au.dk/portal/da/publications/adjuvant-pazopanib-versus-placebo-after-nephrectomy-in-patients-with-localized-or-locally-advancedTest-renal-cell-carcinoma(d58e9d29-c537-477e-8912-ed7748cfa5de).html

المؤلفون: Calandrini, Camilla, Schutgens, Frans, Oka, Rurika, Margaritis, Thanasis, Candelli, Tito, Mathijsen, Luka, Ammerlaan, Carola, van Ineveld, Ravian L, Derakhshan, Sepide, de Haan, Sanne, Dolman, Emmy, Lijnzaad, Philip, Custers, Lars, Begthel, Harry, Kerstens, Hindrik H D, Visser, Lindy L, Rookmaaker, Maarten, Verhaar, Marianne, Tytgat, Godelieve A M, Kemmeren, Patrick, de Krijger, Ronald R, Al-Saadi, Reem, Pritchard-Jones, Kathy, Kool, Marcel, Rios, Anne C, van den Heuvel-Eibrink, Marry M, Molenaar, Jan J, van Boxtel, Ruben, Holstege, Frank C P, Clevers, Hans, Drost, Jarno, UU BETA RESEARCH, Faculteit Diergeneeskunde

المساهمون: Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, Hubrecht Institute for Developmental Biology and Stem Cell Research, UU BETA RESEARCH, Faculteit Diergeneeskunde

المصدر: Nature Communications, 11(1). Nature Publishing Group
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature communications, 11(1):1310. Nature Publishing Group
Nature Communications

مصطلحات موضوعية: 0301 basic medicine, Male, Pathology, Renal Cell/drug therapy, Genotyping Techniques, Cell Culture Techniques, General Physics and Astronomy, Cell Culture Techniques/methods, Nephroma, Mesoblastic/drug therapy, Stem cells, Kidney, Drug Screening Assays, 0302 clinical medicine, Kidney/pathology, Tumor Cells, Cultured, RNA-Seq, Precision Medicine, lcsh:Science, Child, Rhabdoid Tumor/drug therapy, Cancer, Biological Specimen Banks, Netherlands, Adult stem cells, Cultured, Multidisciplinary, Precision Medicine/methods, Biobank, Kidney Neoplasms, Tumor Cells, 3. Good health, Organoids, Gene Expression Regulation, Neoplastic, Mesoblastic/drug therapy, Kidney Neoplasms/drug therapy, 030220 oncology & carcinogenesis, Child, Preschool, Female, Single-Cell Analysis, medicine.medical_specialty, Stromal cell, Adolescent, Science, Antitumor/methods, Drug Screening Assays, Antitumor/methods, Transfection, Wilms Tumor, Article, General Biochemistry, Genetics and Molecular Biology, Paediatric cancer, 03 medical and health sciences, Genetic Heterogeneity, Young Adult, medicine, Organoid, Carcinoma, Humans, Nephroma, Kidney tumour, Nephroma, Mesoblastic, Cancer models, Preschool, Carcinoma, Renal Cell, Rhabdoid Tumor, Neoplastic, Whole Genome Sequencing, Genetic heterogeneity, business.industry, Infant, General Chemistry, DNA Methylation, medicine.disease, Organoids/pathology, 030104 developmental biology, Gene Expression Regulation, Carcinoma, Renal Cell/drug therapy, Wilms Tumor/drug therapy, lcsh:Q, Drug Screening Assays, Antitumor, business, Kidney cancer

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::908c9651a65106083bd59aef2388f9dcTest
https://doi.org/10.1038/s41467-020-15155-6Test